ONO PHARMACEUTICAL CO.,LTD.

August 2, 2013

ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
Phone: +81-6-6263-5670
Fax: +81-6-6263-2950

"Glactiv® tablets"for the oral treatment of type 2 diabetes Contraindication was removed and replaced by careful administration in patients with severe renal insufficiency

Ono Pharmaceutical Co., Ltd. (Head Office: Osaka City; President and Representative Director: Gyo Sagara; "Ono") started notifying medical institutions today that for "Glactiv® tablets (generic name: sitagliptin phosphate hydrate; "Glactiv®")" for the oral treatment of type 2 diabetes, the contraindication was removed and replaced by careful administration in "patients with severe renal insufficiency, including those requiring hemodialysis or peritoneal dialysis" .

Glactiv® requires dosage adjustment to one fourth of the usual dose of 50 mg (i.e. 12.5 mg) when administered to patients with type 2 diabetes who have severe renal insufficiency, but administration of Glactiv® to these patients was contraindicated because there were no formulations that could deliver 12.5 mg of the drug. However, as a result of approval of a modification to the formulation to obtain 25 mg tablets with a break line in June 2013, which allows dosage adjustment, the contraindication was removed and replaced by careful administration in patients with severe renal insufficiency.

Glactiv® has been used in monotherapy/combination therapy for type 2 diabetes according to patient's condition from the early stage of treatment. The change from contraindication to careful administration in patients with severe renal insufficiency has enabled us to offer a wider range of treatment options. ONO expects Glactiv® to make a contribution to patients and healthcare professionals by providing an additional option for the treatment of diabetes in Japan.

＜Major changes to the package insert (indicated by underlined bold text)＞

【 CONTRAINDICATIONS 】

（1）Patients with a history of hypersensitivity to the ingredients of Glactiv®
（2）Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes (These patients require rapid correction of hyperglycemia with intravenous fluids and insulin and Glactiv® should not be administered.)
（3） Patients with severe infection, perioperative patients, and patients with serious trauma (Blood glucose control with insulin injections is desirable and administration of Glactiv® is not appropriate for these patients.)

Patients with severe renal insufficiency, including those requiring hemodialysis or peritoneal dialysis (The concentrations of Glactiv® in blood will be increased. (See Pharmacokinetics.) → Deleted

【 PRECAUTIONS FOR DOSAGE AND ADMNISTRATION 】

(1) This drug is known to be substantially excreted by the kidney. Dosage adjustment is recommended in patients with renal insufficiency using the below table as a guide. [See Careful administration and Pharmacokinetics.]

Renal insufficiency	Ccr (mL/min) Serum Cr Levels(mg/dL)※	Usual dose	Maximum dose
Moderate	30 ≤ Ccr < 50 Men: 1.5 < Cr ≤ 2.5 Women: 1.3 < Cr ≤ 2.0	25 mg once daily	50 mg once daily
Severe and ESDR	**Ccr < 30 Men: Cr > 2.5 Women: Cr > 2.0**	**12.5 mg once daily**	**25 mg once daily**

※Levels approximately corresponding to Ccr

(2) For patients with end-stage renal disease (ESRD), Glactiv® may be administered without regard to the timing of dialysis.

【 PRECAUTIONS 】

1. Careful administration

(1) Patients with moderate **or severe renal insufficiency and patients with ESRD requiring hemodialysis or peritoneal dialysis** [See Precautions for dosage and administration and Pharmacokinetics.]

(2) - (4) No change